Preliminary results from a Phase 1 clinical trial assessing BeiGene's (BGNE) PD-1 inhibitor tislelizumab in urothelial cancer patients showed a positive effect. The data were presented at the ASCO GU Symposium in San Francisco.
15 evaluable UC patients treated with tislelizumab showed a 53% (n=8/15) disease control rate (responders + those with stable cancer) including one complete responder and four partial responders.
On the safety front, the rate of adverse events (AEs) was 88% (n=13/15). The most frequent were fatigue (31%), rash (19%); infusion-related reactions (13%), nausea (13%) and abnormal amounts of protein in urine (13%) (biomarker for kidney stress/damage).
The study is ongoing.
Subscribe for full text news in your inbox